Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
进行中（未招募）
1
20.0%
已完成
3
60.0%
No Longer Available
1
20.0%
暂无批准数据
- TuHURA Biosciences and Kintara Therapeutics have finalized their merger, creating a combined entity named TuHURA Biosciences, Inc., focused on advancing cancer immunotherapies. - The merged company will prioritize TuHURA's technologies, including innate immune response agonists and tumor microenvironment modulators, to combat resistance to cancer immunotherapy. - TuHURA plans to initiate a Phase 3 trial in H1 2025 for IFx-2.0, an innate immune response agonist, as an adjunctive therapy to Keytruda in advanced Merkel Cell Carcinoma. - The merger positions TuHURA to address significant challenges in cancer treatment by overcoming primary and acquired resistance to existing immunotherapies.
- Kintara Therapeutics is set to hold a special meeting on September 20, 2024, to approve its merger with TuHURA Biosciences, aiming to enhance its oncology pipeline. - The REM-001 study has enrolled four patients with cutaneous metastatic breast cancer, showing no treatment-related safety issues and progressing towards Phase 3 dose assessment. - Kintara emphasizes that the merger with TuHURA is crucial for continued operation and funding of the REM-001 study, urging stockholders to vote in favor.
